Display options
Cite
Mastroianni CM, Viscomi C, Ceniti S, et al. Preferences of patients with advanced colorectal cancer for treatment with oral or intravenous chemotherapy. Patient. 2008;1(3):181-7doi: 10.2165/1312067-200801030-00005.
Mastroianni, C. M., Viscomi, C., Ceniti, S., De Simone, R., Filice, A., Gadaleta Caldarola, G., Infusino, S., Manfredi, C., Rea, A., Sandomenico, C., Turano, S., Serranò, F., Condemi, G., Cortese, C., Prantera, T., Palazzo, S. (2008). Preferences of patients with advanced colorectal cancer for treatment with oral or intravenous chemotherapy. The patient, 1(3), 181-7. https://doi.org/10.2165/1312067-200801030-00005
Mastroianni, Candida M, et al. "Preferences of patients with advanced colorectal cancer for treatment with oral or intravenous chemotherapy." The patient vol. 1,3 (2008): 181-7. doi: https://doi.org/10.2165/1312067-200801030-00005
Mastroianni CM, Viscomi C, Ceniti S, De Simone R, Filice A, Gadaleta Caldarola G, Infusino S, Manfredi C, Rea A, Sandomenico C, Turano S, Serranò F, Condemi G, Cortese C, Prantera T, Palazzo S. Preferences of patients with advanced colorectal cancer for treatment with oral or intravenous chemotherapy. Patient. 2008 Jul 01;1(3):181-7. doi: 10.2165/1312067-200801030-00005. PMID: 22272925.
Copy Download .nbib Format: NLM
Share it on

Patient. 2008 Jul 01;1(3):181-7. doi: 10.2165/1312067-200801030-00005.

Preferences of patients with advanced colorectal cancer for treatment with oral or intravenous chemotherapy.

The patient

Candida M Mastroianni, Caterina Viscomi, Silvia Ceniti, Rosanna De Simone, Aldo Filice, Gennaro Gadaleta Caldarola, Stefania Infusino, Caterina Manfredi, Antonio Rea, Claudia Sandomenico, Salvatore Turano, Francesco Serranò, Giovanni Condemi, Carla Cortese, Tullia Prantera, Salvatore Palazzo,

Affiliations

  1. 1 Mariano Santo Hospital, Cosenza, Italy 2 Siderno Hospital, Siderno, Italy 3 San Giovanni di Dio Hospital, Crotone, Italy.

PMID: 22272925 DOI: 10.2165/1312067-200801030-00005

Abstract

BACKGROUND: In recent years, patient-reported outcomes such as health-related quality of life have become important areas of clinician focus in general cancer management. Patients' preferences for, and/or satisfaction with, oral versus intravenous (IV) chemotherapy schedules may have a major impact on such outcomes.

OBJECTIVE: To evaluate preferences for oral or IV chemotherapy in patients with advanced colorectal cancer.

METHODS: A multicenter, randomized, crossover trial was conducted in 12 hospitals in Southern Italy, in which 22 patients with advanced colorectal cancer received one cycle of oral capecitabine ± irinotecan or oxaliplatin, followed by one cycle of an IV de Gramont or similar regimen (arm A), or the same regimens in reverse order (arm B). Patients were aged 50-70 years and 21% had a higher level of education (graduate or similar). Patients received oral capecitabine 3500 mg/m/day for 7 days (± irinotecan 180 mg/m or oxaliplatin 85 mg/m on day 1 only), followed by an IV de Gramont regimen ± irinotecan (FOLFIRI) or oxaliplatin (FOLFOX); or the two schedules administered in reverse order.The main outcome measure was patients' preferences for oral versus IV chemotherapy, as determined by a pre- and post-treatment therapy preference questionnaire (TPQ).

RESULTS: Before treatment, 75% of patients preferred oral therapy. Characteristics that patients considered to be important were that treatment should not interfere with daily activities (100% of patients) and should not cause fatigue (95%), diarrhea (76%), or painful mouth ulcers (76%); other factors considered important were the risk of infection and nausea (90%), and that treatment could be administered at home (65%). After receiving both chemotherapy schedules, only 45% of patients preferred oral therapy, while 55% preferred IV therapy. Among the latter, the most important characteristics influencing treatment choice were less nausea (66%), fewer mood effects (65%), the safety of hospital IV treatment (62%), less interference with family relationships (55%), less vomiting (55%), less interference with daily activities (50%), and less diarrhea (50%). Although the order in which patients received therapy did not influence treatment preference, significantly fewer patients with a lower rather than higher educational level preferred oral therapy (47% vs 80%; chi-square test = 9.9; p = 0.002).

CONCLUSION: These results suggest that there may be a correlation between educational level and the preference of patients with advanced colorectal cancer for oral or IV chemotherapy.

References

  1. Eur J Cancer. 2002 Feb;38(3):349-58 - PubMed
  2. N Engl J Med. 2005 Jun 30;352(26):2696-704 - PubMed
  3. Support Care Cancer. 2008 Feb;16(2):127-32 - PubMed
  4. Eur J Cancer. 1998 Jul;34(8):1274-81 - PubMed
  5. J Clin Oncol. 2003 Oct 1;21(19):3665-75 - PubMed
  6. Br J Cancer. 2006 Apr 24;94(8):1122-9 - PubMed
  7. Soc Sci Med. 1992 Dec;35(12):1505-9 - PubMed
  8. Neth J Med. 2000 Dec;57(6):215-23 - PubMed
  9. Eur J Cancer. 2007 Jul;43(10):1564-73 - PubMed
  10. Eur J Cancer. 1996 Dec;32A(13):2262-6 - PubMed
  11. J Clin Oncol. 2001 Apr 15;19(8):2282-92 - PubMed
  12. J Clin Oncol. 1997 Jan;15(1):110-5 - PubMed
  13. Med J Aust. 2000 Aug 7;173(3):125-7 - PubMed
  14. Ann Oncol. 2006 Feb;17(2):239-45 - PubMed
  15. Surgery. 2001 May;129(5):547-51 - PubMed
  16. Oncologist. 2004;9(2):207-16 - PubMed
  17. J Natl Cancer Inst. 1996 May 15;88(10):668-74 - PubMed
  18. Ann Surg Oncol. 2000 Jul;7(6):441-9 - PubMed
  19. Ann Oncol. 2002 Oct;13(10):1583-9 - PubMed
  20. Br J Cancer. 2007 Dec 3;97(11):1469-74 - PubMed
  21. Br J Cancer. 2004 Mar 22;90(6):1190-7 - PubMed
  22. Eur J Cancer. 1997 Mar;33(3):398-403 - PubMed

Publication Types